
|Articles|November 1, 2003
Vaulting Forth the Vaccine
Boston - Cancer researchers have developed an experimental vaccine that showed promising results in early stage testing for the treatment of metastatic melanoma. The vaccine, which is made by transferring a gene into a patient's own melanoma cells, caused an immune system attack against melanoma tumors, with nearly one-third of 35 patients alive after three years, and four of them with no signs of the disease.
Advertisement
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
First-in-Class Topical GT20029 Demonstrates Promising Phase 2 Efficacy and Tolerability for AGA
2
Medicus Pharma Completes Phase 2 Enrollment of D-MNA Study to Non-Invasively Treat BCC
3
JAK Inhibitors Show Comparable Safety to TNF Antagonists
4
Balancing Pathophysiology and Patient Lifestyle in Acne Management: Part 1
5


















